electroCore (NASDAQ:ECOR – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Volatility & Risk
electroCore has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.
Insider & Institutional Ownership
26.7% of electroCore shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 13.8% of electroCore shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $32.03 million | 1.72 | -$13.97 million | ($1.65) | -4.12 |
| Nutriband | $2.14 million | 20.66 | -$10.48 million | ($3.07) | -1.18 |
Nutriband has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for electroCore and Nutriband, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
electroCore presently has a consensus price target of $18.00, suggesting a potential upside of 164.71%. Given electroCore’s stronger consensus rating and higher probable upside, equities research analysts plainly believe electroCore is more favorable than Nutriband.
Profitability
This table compares electroCore and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -43.60% | -1,956.38% | -74.62% |
| Nutriband | -560.89% | -133.22% | -114.00% |
Summary
electroCore beats Nutriband on 8 of the 14 factors compared between the two stocks.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
